The European Union has issued a lawsuit against AstraZeneca Pharmaceuticals, accusing it of not guaranteeing the release of its vaccine dose against the coronavirus without any valid explanation, and imposing a strict control over the export of manufactured vaccines.
The EU Health Commissioner, Stella Kyriakides, says that the bloc, which is facing critical criticisms of a slow distribution of vacancies in its 27 member states, “takes any action that is necessary to protect its citizens and its rights” .
The EU, which has 450 million citizens and the economic and political weight of the world’s largest commercial block, is at odds with countries such as Israel and Great Britain in the inoculation of its most vulnerable workers and the most vulnerable people .
So ook, ‘n pesar de tener más 400,000 decesos a causa del COVID-19 desde que empezó la pandemia.
The demonstrations in the AstraZeneca undeveloped airway units, which are preceded by the block of medical clearance of the fires, together with the countermeasures in the distribution of the unloaded airway by Pfizer and the German company BioNTech european bajo presión.
“The EU Member States are united: the vacancies for social and contractual responsibilities that must be completed,” commented Kyriakides on the tens of six negotiations sessions with AstraZeneca that will end the night.
Ambas skei volverán a reunirse el miércoles.
Demora is the most annoying debate that the UE has paid 2,700 million euros (3,280 million dollars) in various pharmaceuticals to meet the rapid decline and increase the potential for production of various vacancies, Kyriakides said.
Aggregate that the negotiations entabladas lunes termininaron “con insatisfacción la la lack de claridad y insuficientes explanations”.
The lack of confidence contrasts sharply with the exhilarating tone of having only one month, when the major pharmaceutical giants were quick and massive to unroll a vehicle against a pandemic like being seen in more than one sail.
The EU has agreed to buy 300 million AstraZeneca doses with an option for 100 million additional injections. At the end of last week, the all-British company said it was expected to reduce its initial share from 80 million to 31 million.